J&J's Caplyta meets main goal of bipolar mania study

1

Sept 21 (Reuters) – Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to expanding beyond its

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)